A new class of liquid biopsy test for liver cancer surveillance
EvoLiver™ is the flagship blood test of our hepatology-led strategy, built on Mursla Bio's proprietary tissue-specific extracellular vesicle (TS-EV) platform.
The test is designed for liver cancer surveillance in patients with advanced liver scarring (cirrhosis, including MASH F4), detecting cancer at an early stage, when curative intervention remains possible.
In April 2025, EvoLiver™ received FDA Breakthrough Device Designation, the first granted to any test in the liver cancer surveillance space in at least five years.
We are advancing toward launching EvoLiver™ as a laboratory developed test (LDT). The test is being evaluated in MEV01, a prospective-led multicenter study.
Our initial focus is to transform liver cancer surveillance in high-risk populations. Liver cancer is the fastest-rising cause of cancer-related deaths in the United States.
For example, around 10 million people in the United States and Europe live at high risk of developing liver cancer, often due to a pre-existing medical condition such as cirrhosis, including MASH F4.
However, detection rates remain low because ultrasound lacks sufficient sensitivity for early-stage disease, particularly in overweight individuals. Adherence is also poor: fewer than one in four eligible patients in the United States receive recommended surveillance, in part because it requires a separate imaging appointment rather than fitting into routine blood work.
